Evaluation of the effect of androgen replacement therapy using transdermal testosterone in males with obesity and hypogonadism
Obesity and metabolism · 18.07.2026 · 23 (2) · 4-12
DOI: 10.14341/omet13340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity and metabolism, online erschienen am 18.07.2026. Verfasst von R. V. Rozhivanov und 8 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Being an indication for androgen replacement therapy, male hypogonadism is often associated with obesity. Therefore, assessing the impact of testosterone replacement therapy (TRT) on obesity is relevant. AIMS: To evaluate the impact of transdermal TRT on obesity and quality of life (QOL) in males with hypogonadism. MATERIALS AND METHODS: A comparative, randomized, prospective study enrolled 156 hypogonadal and obese males aged 39 [34; 44] years (the comparison group had no concurrent intervention). Study participants were randomly assigned 1 of the 2 groups by matching appropriate pairs. Group 1 consisted of males receiving transdermal TRT, while Group 2 consisted of patients not receiving androgen therapy but undergoing obesity treatment through diet and lifestyle modification. The observation period was 12 months. A retrospective comparison was also performed on patient subgroups within Group 2, based on whether their hypogonadism was eliminated or persisted. The procedures included collecting patient anamnesis, conducting a physical examination to determine body mass index, administering a questionnaire regarding androgen deficiency symptoms, and assessing total testosterone levels. The Mann–Whitney U-test, Wilcoxon test, and χ² with Yates' correction were employed for group comparisons. A p-value below 0.05 was deemed statistically significant. Multiple comparisons were adjusted using the Bonferroni correction. RESULTS: The groups were comparable regarding the parameters examined at the study's outset. Most of the parameters observed showed statistically significant alterations in both groups 1 and 2, except for hematocrit and hemoglobin levels in group 2. Patients receiving TRT after 12 months from their inclusion into the study had a statistically significantly higher level of total testosterone and lesser severity of androgen deficiency symptoms. When assessing the magnitude of changes in the studied parameters, it was found that patients receiving TRT were characterized by a statistically significantly more pronounced decrease in body weight (mean difference -4.0% (95% CI -5.2; -2.7, р50%) were observed in 23% of men on TRT and 12% of patients without hypogonadism therapy, p=0.098 (χ² with Yates' correction). Hemoglobin elevations above the reference value (>160 g/L) were detected in 37% and 15% of males on TRT and without hypogonadism therapy, respectively (p=0.003; χ² with Yates' correction). No increases in hematocrit or hemoglobin levels requiring discontinuation of TRT were observed. CONCLUSIONS: Treatment of hypogonadism using TRT has a positive effect on weight loss in obese males. Furthermore, normalization of testosterone levels leads to a reduction in androgen deficiency symptoms, accompanied by an improvement in quality of life (QOL). Hypogonadism cessation with obesity treatment alone (without the use of TRT) is possible in 41% (95% CI 30.1-53.3) of cases, provided clinically significant weight loss is achieved. Since most respondents achieved normalization of total testosterone levels within the first 6 months, this allows timely initiation of TRT to those patients who have not achieved stable normalization of total testosterone levels within a specified time.
Zitieren
APA
Rozhivanov, R. V., Morozova, E. V., Ioutsi, V. A., Antsupova, M. A., Savelyeva, L. V., Rozhivanova, E. R., Andreeva, E. N., Mel'nichenko, G. A., & Mokrysheva, N. G. (2026). Evaluation of the effect of androgen replacement therapy using transdermal testosterone in males with obesity and hypogonadism. Obesity and metabolism, 23(2), 4-12. https://doi.org/10.14341/omet13340
Vancouver
Rozhivanov RV, Morozova EV, Ioutsi VA, Antsupova MA, Savelyeva LV, Rozhivanova ER, et al. Evaluation of the effect of androgen replacement therapy using transdermal testosterone in males with obesity and hypogonadism. Obesity and metabolism. 2026;23(2):4-12. doi:10.14341/omet13340
BibTeX
@article{Rozhivanov2026,
author = {Rozhivanov, R. V. and Morozova, E. V. and Ioutsi, V. A. and Antsupova, M. A. and Savelyeva, L. V. and Rozhivanova, E. R. and Andreeva, E. N. and Mel'nichenko, G. A. and Mokrysheva, N. G.},
title = {Evaluation of the effect of androgen replacement therapy using transdermal testosterone in males with obesity and hypogonadism},
journal = {Obesity and metabolism},
year = {2026},
volume = {23},
number = {2},
pages = {4--12},
doi = {10.14341/omet13340}
}
EUVIMED